US009636334B2

(12) **United States Patent**
Pogue et al.

(10) **Patent No.: US 9,636,334 B2**
(45) **Date of Patent: *May 2, 2017**

(54) **COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE CONSTRUCT, AND USES THEREOF**

(71) Applicant: **Teva Pharmaceuticals Australia Pty, Ltd**, Macquarie Park, NSW (AU)

(72) Inventors: **Sarah L. Pogue**, Frazer, PA (US); **David S. Wilson**, Frazer, PA (US); **Anthony Gerard Doyle**, Drummoyne (AU); **Collette Jane Behrens**, Macquarie Park (AU)

(73) Assignee: **Teva Pharmaceuticals Australia Pty Ltd**, Macquarie Park, NSW (AU)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/701,628**

(22) Filed: **May 1, 2015**

(65) **Prior Publication Data**

US 2015/0313965 A1 Nov. 5, 2015

Related U.S. Application Data

(60) Provisional application No. 61/986,913, filed on May 1, 2014.

(51) **Int. Cl.**

A61K 39/395	(2006.01)
A61K 38/21	(2006.01)
A61K 31/454	(2006.01)
C07K 16/28	(2006.01)
C07K 14/56	(2006.01)
A61K 45/06	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/454*** (2013.01); ***A61K 38/212*** (2013.01); ***A61K 39/39558*** (2013.01); ***A61K 45/06*** (2013.01); ***C07K 14/56*** (2013.01); ***C07K 16/28*** (2013.01); ***C07K 16/2896*** (2013.01); *C07K 2319/035* (2013.01); *C07K 2319/33* (2013.01)

(58) **Field of Classification Search**

CPC A61K 31/454; A61K 38/212; A61K 39/39558; C07K 14/56; C07K 16/2896; C07K 16/28

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,545,405 A	8/1996	Page	
6,602,684 B1	8/2003	Umana et al.	
7,083,784 B2	8/2006	Dall'Acqua et al.	
7,217,797 B2	5/2007	Hinton et al.	
7,326,681 B2	2/2008	Gerngross	
7,388,081 B2	6/2008	Seki et al.	
7,732,578 B2	6/2010	Foote	
7,829,673 B2	11/2010	De Weers et al.	
8,088,896 B2	1/2012	Tesar et al.	
8,153,765 B2	4/2012	Park et al.	
2002/0164788 A1	11/2002	Ellis et al.	
2003/0211553 A1	11/2003	Logtenberg et al.	
2009/0068175 A1	3/2009	Lazar et al.	
2009/0076249 A1	3/2009	De Weers et al.	
2009/0092599 A1	4/2009	Lazar et al.	
2009/0123950 A1	5/2009	Tesar	
2009/0142340 A1	6/2009	Lazar et al.	
2010/0172868 A1	7/2010	Morrison et al.	
2010/0189689 A1	7/2010	Chang et al.	
2010/0285004 A1	11/2010	Tesar et al.	
2012/0201827 A1*	8/2012	Elias	C12N 9/99 424/139.1
2013/0302318 A1*	11/2013	Rojkjaer	A61K 31/454 424/133.1
2014/0248238 A1*	9/2014	Wilson, Jr.	C07K 16/1027 424/85.5
2016/0068612 A1*	3/2016	Clarke	C07K 14/56 424/85.7
2016/0122410 A1*	5/2016	Behrens	C07K 14/56 424/85.7

FOREIGN PATENT DOCUMENTS

WO	0042072	7/2000
WO	0197844	12/2001
WO	2005103083	11/2005
WO	2006099875	9/2006
WO	WO2006/125640 A2 *	11/2006
WO	2007042309	4/2007
WO	2008006554	1/2008

(Continued)

OTHER PUBLICATIONS

Richardson et al., Br. J. Haematol., 2011; 154:745-54.*

(Continued)

Primary Examiner — Jessica H Roark

(74) *Attorney, Agent, or Firm* — Stradley Ronon Stevens & Young, LLP

(57) **ABSTRACT**

Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.

20 Claims, 9 Drawing Sheets